Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01723020 : A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
PhasePhase 1
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Men or women > 18 years old

- Pathologically documented, definitively diagnosed, advanced solid tumor that is
refractory to standard treatment, or which no standard therapy is available, or the
subject refuses standard therapy or multiple myeloma

- Willing to undergo pre-dose core needle tumor biopsies or bone marrow aspirate for
subjects with multiple myeloma.

- Ability to take oral medications and willing to record daily adherance to
investigational product

- Adequate hematological, renal, hepatic, and coagulation laboratory assessments

Exclusion Criteria:

- Active brain metastases

- For solid tumor-History or presence of hematological malignancies unless curatively
treated with no evidence of disease for greater than or equal to 5 years

- Active infection requiring intravenous (IV) antibiotics

- Anti-tumor therapy

- Therapeutic or palliative radiation therapy within 30 days of starting treatment

- Currently enrolled in another investigational device or drug study
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557